0.6087
전일 마감가:
$0.58
열려 있는:
$0.58
하루 거래량:
906.20K
Relative Volume:
0.52
시가총액:
$46.46M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-30.43
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+2.46%
1개월 성능:
-10.12%
6개월 성능:
-47.07%
1년 성능:
-71.56%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
0.6087 | 46.46M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
2022-06-24 | 개시 | BMO Capital Markets | Outperform |
2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
2021-11-15 | 개시 | BTIG Research | Buy |
2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2021-03-29 | 개시 | JP Morgan | Overweight |
2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
2020-05-14 | 재확인 | H.C. Wainwright | Buy |
2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
2020-03-04 | 개시 | Barclays | Equal Weight |
2019-11-20 | 개시 | Guggenheim | Buy |
2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-06-13 | 개시 | Mizuho | Buy |
2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
2019-03-11 | 개시 | Barclays | Overweight |
2018-11-26 | 개시 | Piper Jaffray | Overweight |
2018-10-15 | 개시 | Goldman | Neutral |
2018-09-13 | 개시 | H.C. Wainwright | Buy |
2018-06-01 | 개시 | SunTrust | Buy |
2018-01-05 | 개시 | Citigroup | Buy |
2017-09-08 | 개시 | Wedbush | Outperform |
2017-03-27 | 개시 | H.C. Wainwright | Buy |
2017-03-02 | 개시 | Instinet | Buy |
2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World
Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX
CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World
StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN
CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada
Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India
CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada
CytomX Therapeutics CEO sells $22,555 in stock - Investing.com India
CytomX Therapeutics Executives Sell Shares for Tax Obligations - TradingView
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com
CytomX therapeutics general counsel sells $6,111 in stock By Investing.com - Investing.com UK
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com Australia
CytomX at Barclays Healthcare: Probody Platform Progress By Investing.com - Investing.com South Africa
CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World
What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - stocksregister.com
CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter
CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey
CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now - Insider Monkey
Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - Citeline News & Insights
Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks - TipRanks
CytomX stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - The Manila Times
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
CytomX Therapeutics Inc earnings beat by $0.43, revenue topped estimates - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Reports Strong 2024 Financial Results - TipRanks
CytomX To Report Colorectal Cancer Trial Data Of CX-2051 In 1H, 2025 - Nasdaq
CytomX Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):